BioInvent International
29,1
SEK
+3,19 %
Mindre end 1K følgere
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+3,19%
-8,06%
+2,46%
-24,42%
-32,64%
+24,89%
-35,55%
-25,01%
-96,95%
BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.
Læs mereMarkedsværdi
1,91 mia. SEK
Aktieomsætning
1,77 mio. SEK
Omsætning
44,69 mio.
EBIT %
-1.054,06 %
P/E
-
Udbytteafkast, %
-
Finanskalender
29.4
2025
Generalforsamling '25
29.4
2025
Delårsrapport Q1'25
26.8
2025
Delårsrapport Q2'25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
BioInvent International AB publishes Annual Report 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
BioInvent to Participate in Upcoming Investor Conferences
Notice to Annual General Meeting in BioInvent International AB
BioInvent International AB: BioStock: BioInvent's BI-1808 gains broad FDA support
BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum
BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma
Redeye: BioInvent Q4 2024 - January Readout an Anticlimax
BioInvent International AB: BioStock: BioInvent prepares for a data-rich 2025
